We will present our recent advancements in the development of a biological drug for treatment of chronic inflammatory diseases. Pre-clinical results based on well established models have shown the importance of our novel target molecule, the bile-salt stimulated lipase (BSSL). The development of a humanised antibody is in progress and Lipum is actively seeking partners [...]
Lipum offer a new route for treatment of chronic inflammatory diseases such as rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA). Contact us and meet with our CEO Einar Pontén or Chairman Ulf Björklund at BIO-Europe Spring 2017 in Barcelona. We will tell you more on our novel target bile salt-stimulated lipase (BSSL) and our ongoing development [...]
Meet Lipum at Sachs Associates 10th Annual ELSCEO Forum & Exhibition, on 6-7th March 2017 at the Hilton Zürich Airport Hotel, Switzerland. This event bring together a cross-section of venture-funded and small-cap companies with leading investors, pharmas, and scientific thought leaders. Please contact us to book a meeting on March 6-7, 2017.
Biotech Umeå Investment Day 2017 at Grand Hotel in Stockholm is a partnering event, for startups, investors and industrial partners within life science. Please contact us and book a meeting in Stockholm on February 2, 2017.
Lipum is actively seeking partners and investors for a faster development of a new biological drug towards an unique target for treatment of autoimmune inflammatory diseases. Swiss Nordic Bio in Zürich is a high-level partnering and investor event where Swiss and Nordic biotech startups, pharmaceutical companies and investors meet. Please contact us an book a [...]
The Board of Directors of Lipum AB in Umeå has appointed Dr Einar Pontén new CEO. "We are very pleased to recruit an experienced force when Lipum face a very exciting development," said Chairman Ulf Björklund. Link to press release in Swedish»